Chromatin

Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting

Retrieved on: 
星期一, 十二月 5, 2022
Foghorn, BRG1, Cell, ClinicalTrials.gov, Protein, Leukemia, SMARCA4, ATPase, Security (finance), MDS, Poster, Cancer, Bone marrow, Choroid, Gene expression, Acute leukemia, ASH, Pharmacology, BAF, BRM, Iris, AML, Ciliary body, SMARCA2, Acute myeloid leukemia, Drug resistance, Research, Society, Chromatin, Therapy, Blood, Patient, MD Anderson Cancer Center, Pharmaceutical industry, Dietary supplement, Science

Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III

Key Points: 
  • Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III
    The poster will be accessible following the presentation under the Science section of the Company’s website.
  • In preclinical studies, FHD-286 has shown anti-tumor activity across a broad range of malignancies including both hematologic and solid tumors.
  • Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system.
  • Any forward-looking statement made in this press release speaks only as of the date on which it is made.

Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference

Retrieved on: 
星期二, 十一月 22, 2022
Conference, Evercore, Gene expression, Therapy, Chromatin, Foghorn, Pharmaceutical industry

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Adrian Gottschalk, President and Chief Executive Officer, will participate in the Evercore ISI HealthCONx Conference which will be held virtuallyon November 30, 2022.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Adrian Gottschalk, President and Chief Executive Officer, will participate in the Evercore ISI HealthCONx Conference which will be held virtuallyon November 30, 2022.
  • With an initial focus in oncology, Foghorns Gene Traffic Control Platform and resulting broad pipeline have the potential to transform the lives of people with a wide spectrum of diseases.
  • FoghornTherapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system.
  • Through its proprietary and scalable Gene Traffic Control platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system.

Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
星期一, 十一月 21, 2022
Marketing, CD3, Endometrial cancer, SMILE, Cancer, Female, Context, Therapy, Patient, Chromatin, CLDN6, PR, Breast cancer, Breast, Medical imaging, Pharmaceutical industry

PHILADELPHIA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Context or the Company) (Nasdaq: CNTX), a womens oncology company developing novel treatments for breast and gynecologic cancers, today announced clinical data on onapristone extended release (ONA-XR) will be presented at the 2022 San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, Texas, from December 6-10, 2022.

Key Points: 
  • PHILADELPHIA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Context or the Company) (Nasdaq: CNTX), a womens oncology company developing novel treatments for breast and gynecologic cancers, today announced clinical data on onapristone extended release (ONA-XR) will be presented at the 2022 San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, Texas, from December 6-10, 2022.
  • Preliminary preclinical and clinical data suggest that ONA-XR has anticancer activity by inhibiting progesterone receptor binding to chromatin, downregulating cancer stem cell mobilization and blocking immune evasion.
  • ONA-XR is currently being evaluated in three Phase 2 clinical trials and one Phase 1b/2 clinical trial in PR+ breast, ovarian and endometrial cancers.
  • Context Therapeutics Inc. (Nasdaq: CNTX)is a clinical-stage biopharmaceutical company committed to advancing medicines for female cancers.

Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting

Retrieved on: 
星期一, 十一月 14, 2022
Vancouver Convention Centre, Sarcoma, Clinical trial, Gene expression, Poster, Chromatin, Annual general meeting, Ligament, Therapy, Research, Security (finance), BRD9, Synovial sarcoma, Foghorn, Treatment, Medical device, Pharmaceutical industry, Science

The meeting will be held November 1619, 2022, at the Vancouver Convention Centre in Vancouver, BC, Canada.

Key Points: 
  • The meeting will be held November 1619, 2022, at the Vancouver Convention Centre in Vancouver, BC, Canada.
  • Synovial sarcoma is a rare, often aggressive soft tissue sarcoma that originates from different types of soft tissue, including muscle or ligaments.
  • It represents around 510% of all soft tissue sarcomas, with ~800 new cases each year in the United States.
  • Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system.

Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting

Retrieved on: 
星期三, 十一月 9, 2022
GLOBE, Choroid, Forward-looking statement, Protein, Convention center, Foghorn, Ciliary body, U.S. Securities and Exchange Commission, Annual general meeting, Nasdaq, Immunotherapy, Research, Myelodysplastic syndrome, Cancer, Acute leukemia, Acute myeloid leukemia, Boston Convention and Exhibition Center, Bone marrow, SMARCA4, Therapy, Gene expression, ClinicalTrials.gov, Survival, Chromatin, Blood, BRG1, BAF, AML, Poster, Cell, Patient, MDS, BRM, Iris, SMARCA2, Security (finance), ATPase, Society, Adult, SITC, Pharmaceutical industry, Dietary supplement, Science

The meeting will be held November 812, 2022, at the Boston Convention and Exhibition Center and virtually.

Key Points: 
  • The meeting will be held November 812, 2022, at the Boston Convention and Exhibition Center and virtually.
  • The poster will highlight new data demonstrating the potential of FHD-286, in combination with an anti-PD-1 antibody, to provide synergistic efficacy and survival benefit compared to anti-PD-1 alone in preclinical models.
  • In preclinical studies, FHD-286 has shown anti-tumor activity across a broad range of malignancies including both hematologic and solid tumors.
  • Any forward-looking statement made in this press release speaks only as of the date on which it is made.

Cell Reprogramming Market Share, Size, Trends, Industry Analysis Report, By Technology, By Application, By End-Use, By Region, Segment Forecast, 2022 - 2030 - ResearchAndMarkets.com

Retrieved on: 
星期一, 十月 31, 2022
Research, Pharmaceutical, Infectious Diseases, Hospitals, Genetics, Health Technology, Clinical Trials, Science, COVID-19, Biotechnology, Stem Cells, Health, Other Science, COVID-19, RNA transfection, Growth, DNA, Traction, Human parainfluenza viruses, Tissue, Efficiency, Research, Revenue, CMYC, Chromatin, Cell, Regenerative medicine, Investment, USD, Gene editing, Tissue engineering, ES, Glossary of genetics, Renewable energy, Medical imaging, Vaccine, Pharmaceutical industry, Technology, Application, Oct-4

The "Cell Reprogramming Market Share, Size, Trends, Industry Analysis Report, By Technology, By Application, By End-Use, By Region, Segment Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Reprogramming Market Share, Size, Trends, Industry Analysis Report, By Technology, By Application, By End-Use, By Region, Segment Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global cell reprogramming market size is expected to reach USD 618.00 million by 2030 according to a new study.
  • The report "Cell Reprogramming Market Share, Size, Trends, Industry Analysis Report, By Technology (Sendai Virus, mRNA, Episomal); By Application (Research, Therapeutic); By End-Use; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.
  • The publisher has segmented the cell reprogramming market report based on form, application, end use and region:
    Cell Reprogramming, Technology Outlook (Revenue - USD Million, 2018 - 2030)

Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors

Retrieved on: 
星期四, 十月 27, 2022
Chromatin, Yale Cancer Center, Company, Drug development, Security (finance), LinkedIn, U.S. Securities and Exchange Commission, Board of directors, Nasdaq, Cancer, Forward-looking statement, Bristol Myers Squibb, Fred Hutchinson Cancer Research Center, Foghorn, Gene expression, Board, Leadership, Fred, Research, GLOBE, Twitter, Therapy, Massachusetts General Hospital, Hospital, Pharmaceutical industry, Management

Douglas Cole, M.D., Flagship Pioneering Managing Partner, Foghorn Co-Founder and Chairman of the Board, continued, We are thrilled to welcome Tom to the Foghorn Board.

Key Points: 
  • Douglas Cole, M.D., Flagship Pioneering Managing Partner, Foghorn Co-Founder and Chairman of the Board, continued, We are thrilled to welcome Tom to the Foghorn Board.
  • I am excited to be joining the board ofFoghorn and I look forward to collaborating with the other board members and the Foghorn team during this important stage of Foghorns journey, saidDr.
  • Foghorn Therapeutics Inc. is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system.
  • Any forward-looking statement made in this press release speaks only as of the date on which it is made.

Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program

Retrieved on: 
星期三, 十月 26, 2022
Lung, Synovial sarcoma, Chromatin, Company, Clinical trial, Security (finance), CBP, LinkedIn, U.S. Securities and Exchange Commission, Safety, Nasdaq, Forward-looking statement, Immunomodulatory imide drug, Hanson, Foghorn, Gene expression, Patient, Breast, IV, Research, GLOBE, Twitter, Therapy, BRD9, Ligament, Selective, Sarcoma, Cancer, CREB, Vaccine, Pharmaceutical industry, EP300

CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today will present new data across its protein degradation platform at Hanson Wade’s 5th Annual Targeted Protein Degradation Summit. Early clinical data from the ongoing Phase 1 study of FHD-609 in synovial sarcoma and preclinical data from a newly disclosed program targeting CREB binding protein (CBP) in EP300 mutated cancers reinforce Foghorn’s significant advancement across its protein degradation platform and pipeline.

Key Points: 
  • We demonstrate highly potent and specific degradation of BRD9 with FHD-609 and, more significantly, in vivo loss of BRD9 in patient solid tumors.
  • Additionally, we are excited to announce our new protein degrader program, Selective CBP, which has potential broad therapeutic applications in cancer.
  • Foghorn will also include preclinical data highlighting the development of an orally bioavailable BRD9 selective degrader, demonstrating capabilities for both oral and IV formulations.
  • During the conference, Foghorn will also disclose the addition of its selective CBP degrader targeting EP300 mutant cancers to its pipeline.

Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit

Retrieved on: 
星期四, 十月 20, 2022
U.S. Securities and Exchange Commission, LinkedIn, Forward-looking statement, Therapy, Twitter, Chromatin, Research, Security (finance), Foghorn, Pharmaceutical industry, Bookkeeping

Through its proprietary and scalable Gene Traffic Control platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system.

Key Points: 
  • Through its proprietary and scalable Gene Traffic Control platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system.
  • The company is developing multiple product candidates in oncology with two currently being investigated in clinical studies.
  • Visit our website at www.foghorntx.com for more information on the company, and follow us on Twitter and LinkedIn .
  • Any forward-looking statement made in this press release speaks only as of the date on which it is made.

Trilogene Seeds Accelerates Cannabis Biotech Research at SIU's Saluki Innovation Lab

Retrieved on: 
星期三, 十月 19, 2022
Gene expression, Germination, Cannabis, Seed, Marker beacon, AG, Biotechnology, Breeding, Chromatin, Research, Biomass, Immunoprecipitation, Multimedia, Compliance, Doctor of Philosophy, THC, SIU, Economic development, Domestication, Genetics, DNA, USDA, University City (Charlotte neighborhood), Gene, View, Agriculture

CARBONDALE, Ill., Oct. 19, 2022 /PRNewswire/ -- Trilogene Seeds announces advanced hemp research initiative at Saluki Innovation Lab at Southern Illinois University Research Park.

Key Points: 
  • CARBONDALE, Ill., Oct. 19, 2022 /PRNewswire/ -- Trilogene Seeds announces advanced hemp research initiative at Saluki Innovation Lab at Southern Illinois University Research Park.
  • The team plans to leverage genomic tools and agricultural biotechnology with the aim of developing and breeding cannabis and hemp genetics of the future.
  • "We are committed to accelerating the development of this complex plant and will continue to push research forward at our new genomics lab in Illinois.
  • This opportunity at SIU's innovation center will allow us to lean on university expertise and infrastructure to accelerate our genetic development projects," says Matt Haddad, CEO/Founder of Trilogene Seeds.